Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
120.00    0.60 (0.50%)
Bid:
119.40
Ask:
120.00
Spread: 0.60 (0.503%)
Market Cap: £292.10m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Transaction in Own Shares

21 Dec 2023 07:00

RNS Number : 5312X
PureTech Health PLC
21 December 2023
 

21 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

20 December 2023

Number of ordinary shares purchased:

31,948

Highest price paid per share:

154.80p

Lowest price paid per share:

152.00p

Volume weighted average price paid per share:

154.25p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,517,641 ordinary shares in treasury and has 271,950,518 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 271,950,518 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

20/12/2023

08:01:52

583

154.6

CHIX

00383161287TRLO0.1.1

20/12/2023

08:01:52

583

154.4

BATE

00383161288TRLO0.1.1

20/12/2023

08:01:52

583

154.6

XLON

00383161289TRLO0.1.1

20/12/2023

08:01:52

193

154.6

TRQX

00383161290TRLO0.1.1

20/12/2023

08:01:56

356

154.4

AQXE

00383161302TRLO0.1.1

20/12/2023

09:00:18

583

154.8

CHIX

00383171418TRLO0.1.1

20/12/2023

09:00:18

583

154.8

XLON

00383171419TRLO0.1.1

20/12/2023

09:02:41

583

153.6

XLON

00383171777TRLO0.1.1

20/12/2023

10:43:29

356

154.2

AQXE

00383188137TRLO0.1.1

20/12/2023

10:43:29

583

154

BATE

00383188139TRLO0.1.1

20/12/2023

10:43:29

583

154.2

CHIX

00383188138TRLO0.1.1

20/12/2023

10:43:29

415

154.2

XLON

00383188140TRLO0.1.1

20/12/2023

10:43:29

1334

154.2

XLON

00383188141TRLO0.1.1

20/12/2023

10:43:29

45

153.8

TRQX

00383188142TRLO0.1.1

20/12/2023

10:43:29

148

153.8

TRQX

00383188143TRLO0.1.1

20/12/2023

10:43:29

2

153.8

TRQX

00383188144TRLO0.1.1

20/12/2023

10:43:29

8

153.8

TRQX

00383188145TRLO0.1.1

20/12/2023

10:43:29

6

153.8

TRQX

00383188146TRLO0.1.1

20/12/2023

10:56:34

338

154

CHIX

00383190461TRLO0.1.1

20/12/2023

11:11:09

471

154.2

CHIX

00383192812TRLO0.1.1

20/12/2023

11:23:19

112

154.2

CHIX

00383194421TRLO0.1.1

20/12/2023

11:25:29

19

153.8

BATE

00383194647TRLO0.1.1

20/12/2023

11:27:50

363

153.8

BATE

00383194887TRLO0.1.1

20/12/2023

11:28:30

201

153.8

BATE

00383194956TRLO0.1.1

20/12/2023

11:28:30

583

153.8

CHIX

00383194957TRLO0.1.1

20/12/2023

11:29:55

823

153.4

XLON

00383195253TRLO0.1.1

20/12/2023

11:29:55

343

153.4

XLON

00383195254TRLO0.1.1

20/12/2023

11:52:12

533

152.2

CHIX

00383198720TRLO0.1.1

20/12/2023

11:52:12

1749

152.2

XLON

00383198721TRLO0.1.1

20/12/2023

11:52:12

433

152

XLON

00383198722TRLO0.1.1

20/12/2023

11:52:13

13

152

XLON

00383198723TRLO0.1.1

20/12/2023

12:37:56

16

153

XLON

00383205119TRLO0.1.1

20/12/2023

12:39:35

1200

153.8

XLON

00383205315TRLO0.1.1

20/12/2023

12:39:35

549

153.8

XLON

00383205316TRLO0.1.1

20/12/2023

13:01:54

3036

154.4

XLON

00383209664TRLO0.1.1

20/12/2023

13:01:55

105

154.4

CHIX

00383209672TRLO0.1.1

20/12/2023

13:01:55

773

154.4

CHIX

00383209673TRLO0.1.1

20/12/2023

14:40:57

356

154.8

AQXE

00383243718TRLO0.1.1

20/12/2023

14:40:57

583

154.8

CHIX

00383243720TRLO0.1.1

20/12/2023

14:40:57

583

154.8

BATE

00383243719TRLO0.1.1

20/12/2023

14:40:57

177

154.8

TRQX

00383243721TRLO0.1.1

20/12/2023

14:40:57

237

154.8

XLON

00383243722TRLO0.1.1

20/12/2023

14:40:57

144

154.8

XLON

00383243723TRLO0.1.1

20/12/2023

14:40:57

184

154.8

XLON

00383243725TRLO0.1.1

20/12/2023

14:40:57

18

154.8

XLON

00383243724TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243726TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243727TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243728TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243729TRLO0.1.1

20/12/2023

14:40:57

539

154.8

XLON

00383243730TRLO0.1.1

20/12/2023

14:40:57

607

154.8

XLON

00383243731TRLO0.1.1

20/12/2023

14:40:57

20

154.8

XLON

00383243732TRLO0.1.1

20/12/2023

15:49:32

356

154.8

AQXE

00383277253TRLO0.1.1

20/12/2023

15:49:32

583

154.8

BATE

00383277254TRLO0.1.1

20/12/2023

15:49:32

1166

154.8

CHIX

00383277256TRLO0.1.1

20/12/2023

15:49:32

193

154.8

TRQX

00383277258TRLO0.1.1

20/12/2023

15:49:32

596

154.8

XLON

00383277259TRLO0.1.1

20/12/2023

15:49:32

729

154.8

XLON

00383277260TRLO0.1.1

20/12/2023

15:49:32

2756

154.8

XLON

00383277261TRLO0.1.1

20/12/2023

15:49:32

583

154.8

XLON

00383277262TRLO0.1.1

20/12/2023

15:57:29

19

154.4

AQXE

00383281074TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTFVLIFIV
Date   Source Headline
9th Jul 20267:00 amRNSDirector/PDMR Shareholding
2nd Jul 20267:01 amRNSPRTC Launches Celea w/ $180M & Top Tier Syndicate
2nd Jul 20267:00 amRNSPRTC Launches Celea: $180M & Asset Transfer
10th Jun 20265:38 pmRNSResult of AGM
9th Jun 20267:00 amRNS-RPRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
4th Jun 20265:37 pmRNSHolding(s) in Company
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.